Welcome to Iaso Therapeutics
Vaccines have protected humankind from many deadly infections including smallpox, yellow fever, and tetanus, saving millions of lives. However, the rampage of the COVID-19 over the world serves as a painful reminder of the lack of effective vaccines against many other diseases. Novel technologies that can be readily deployed for new vaccines, especially against newly emerged pathogens, are urgently needed.
Iaso Therapeutics is dedicated to developing next generation vaccines to enhance human health and treat diseases.
Mutant Qβ Platform
Iaso’s initial product offering is a disruptive new virus-like particle, mutant Qβ, that shows superiority in generating antibodies of interest when compared to conjugate carrier proteins like Keyhole Limpet Hemocyanin, diphtheria toxoid, tetanus toxoid, and cross reactive material-197 (CRM-197).
Company News
Iaso Selected for the Renaissance Venture Capital Startup Hotlist
Iaso Therapeutics has been included on the @Renaissance Venture Capital Spring 2023 Startup Hotlist! The Hotlist features some of the most promising early-stage companies from the Midwest, curated from hundreds of recommendations from VC [...]
Iaso Therapeutics Announces First Close in $1.25M Equity Series Seed Preferred Financing
Iaso Therapeutics, a Michigan State University startup developing novel technologies for next-generation vaccines, recently closed the first tranche of the company’s $1.25M Series Seed Preferred round of financing.
